---
document_datetime: 2025-01-15 16:23:21
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/hemgenix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: hemgenix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.9563327
conversion_datetime: 2025-12-26 18:51:29.159337
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Hemgenix

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0024/G            | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where | 16/12/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | batch control/testing takes place B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                  |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0018 | Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to reflect a modified 9-point anti-AAV5 Neutralising Antibody (NAb) assay. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and update the list of local representatives in the Package Leaflet and bring the PI in line with the QRD version 10.4. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 12/12/2024 |            | SmPC and PL | SmPC new text: Preexisting neutralising anti-AAV5 antibodies above a titre of 1:898, based on the neutralising anti-AAV5 antibody assay with extended measuring range (equivalent to 1:678 titre based on the previous clinical study assay), may impede transgene expression at desired therapeutic levels and thus reduce the efficacy of Hemgenix therapy. For more information, please refer to the Summary of Product Characteristics. |
| IA/0025 | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                    | 11/12/2024 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| R/0020  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                | 17/10/2024 | 04/12/2024 |             | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the                                                                                                  |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |                 | renewal of the conditional MA for Hemgenix, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0023/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites | 03/12/2024 |     | Annex II and PL |                                                                                                                                           |
| IB/0022   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 05/11/2024 | n/a |                 |                                                                                                                                           |
| II/0016/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 19/09/2024 | n/a |                 |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|         | B.II.b.2.c.3 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and any of the test methods is a biol/immunol/immunochemical method B.II.b.2.c.3 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and any of the test methods is a biol/immunol/immunochemical method B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation            |            |            |          |                |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|----------------|
| II/0015 | Submission of the final report from study AMT-061- 01/CSL222_2001 listed as a Specific Obligation in the Annex II of the Product Information. This is a Phase IIb, open-label, single-dose, single-arm, multi- center trial to confirm the factor IX activity level of the serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene (AAV5-hFIXco-Padua, AMT- 061) administered to adult subjects with severe or moderately severe hemophilia B. The Annex II is updated to reflect the fulfilment of this commitment. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of | 19/09/2024 | 04/12/2024 | Annex II | Not applicable |

<div style=\"page-break-after: always\"></div>

|           | which require to be further substantiated new additional data to be submitted by the MAH significant assessment is required                                                                                                                                                                                                                                                                                                                                                                          |            |     | change(s) by where   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------|
| II/0014/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test is a biol/immunol method | 19/09/2024 | n/a | method at the site   |
| IB/0021   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                  | 17/09/2024 | n/a |                      |
| IB/0017/G | This was an application for a group of variations. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New of MCB and/or WCB                                        | 05/08/2024 | n/a | storage site         |

<div style=\"page-break-after: always\"></div>

|                     | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient   |            |            |             |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/11037 /202311 | Periodic Safety Update EU Single assessment - etranacogene dezaparvovec                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 13/06/2024 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0012             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 21/02/2024 | n/a        |             |                                   |
| IA/0013             | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 13/02/2024 | 04/12/2024 | SmPC and PL |                                   |
| PSUSA/11037 /202305 | Periodic Safety Update EU Single assessment - etranacogene dezaparvovec                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11/01/2024 | n/a        |             | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| II/0009/G   | This was an application for a group of variations. B.II.b.2.c.3 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and any of the test methods is a biol/immunol/immunochemical method B.II.b.2.c.3 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and any of the test methods is a biol/immunol/immunochemical method B.II.b.2.c.3 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and any of the test methods is a biol/immunol/immunochemical method B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP -   | 14/12/2023   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0007      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 12/10/2023   | 07/12/2023 | The CAT and CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Hemgenix, subject to the Specific Obligations and Conditions as laid down in |
| IB/0010     | B.I.a.2.a - Changes in the manufacturing process of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 23/11/2023   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | AS - Minor change in the manufacturing process the AS                                                                                                                                                                                                                                                                                                                                                |            |            |    | the of                         |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|--------------------------------|
| IB/0006/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                  | 07/08/2023 | n/a        |    |                                |
| IB/0005   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                  | 17/07/2023 | n/a        |    |                                |
| N/0003    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                     | 19/06/2023 | 07/12/2023 | PL |                                |
|           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change process | 05/04/2023 | n/a        |    | IB/0001/G in the manufacturing |

<div style=\"page-break-after: always\"></div>

| N/0002   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   | 23/03/2023   | 07/12/2023   | PL   |
|----------|----------------------------------------------------------------------------------------------------|--------------|--------------|------|